GBM
MCID: GLB002
MIFTS: 68

Glioblastoma (GBM) malady

Categories: Rare diseases, Neuronal diseases, Genetic diseases

Aliases & Classifications for Glioblastoma

Aliases & Descriptions for Glioblastoma:

Name: Glioblastoma 50 56 29 52 69
Glioblastoma Multiforme 50 56 69
Gbm 56

Characteristics:

Orphanet epidemiological data:

56
glioblastoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: adult;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Orphanet 56 ORPHA360
MESH via Orphanet 43 D005909
UMLS via Orphanet 70 C0017636 C1621958
ICD10 via Orphanet 34 C71.9

Summaries for Glioblastoma

NIH Rare Diseases : 50 glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. these cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. glioblastomas are often very aggressive and grow into surrounding brain tissue. signs and symptoms, such as headache, nausea, vomiting and/or drowsiness, may develop when the tumor begins to put excess pressure on the brain. affected people may also experience other features depending on the size and location of the tumor. in most cases, the exact underlying cause is unknown; however, they can rarely occur in people with certain genetic syndromes such as neurofibromatosis type 1, turcot syndrome and li fraumeni syndrome. there is currently no cure for glioblastoma. treatment is palliative and may include surgery, radiation therapy and/or chemotherapy. last updated: 1/19/2015

MalaCards based summary : Glioblastoma, also known as glioblastoma multiforme, is related to glioma susceptibility 2 and grade iii astrocytoma, and has symptoms including headache and seizures. An important gene associated with Glioblastoma is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and t cells, and related phenotypes are Decreased viability and homeostasis/metabolism

Wikipedia : 71 Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins... more...

Related Diseases for Glioblastoma

Diseases in the Glioblastoma family:

Glioblastoma 3

Diseases related to Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 356)
id Related Disease Score Top Affiliating Genes
1 glioma susceptibility 2 31.7 EGFR PIK3CA PTEN
2 grade iii astrocytoma 29.3 CDK4 CDKN2A EGFR MDM2 MGMT PTEN
3 colorectal cancer 28.9 CDK2 CDK4 CDKN2A EGFR ERBB2 MDM2
4 giant cell glioblastoma 12.2
5 glioblastoma multiforme 12.2
6 brain glioblastoma multiforme 12.0
7 glioblastoma 3 12.0
8 glioblastoma classical subtype 11.9
9 glioblastoma proneural subtype 11.9
10 glioblastoma mesenchymal subtype 11.9
11 glioblastoma neural subtype 11.9
12 goodpasture syndrome 11.8
13 adult spinal cord glioblastoma multiforme 11.8
14 gliosarcoma 11.6
15 glioma susceptibility 1 11.6
16 gliomatosis cerebri 11.2
17 glioma susceptibility 9 10.7
18 mismatch repair cancer syndrome 10.7
19 pineal region mature teratoma 10.4 EGFR ERBB2
20 astrocytoma 10.4
21 childhood embryonal testis carcinoma 10.4 EGFR PTEN TP53
22 paternal uniparental disomy of chromosome 1 10.4 EGFR PDGFRA TP53
23 rommen mueller sybert syndrome 10.4 CDK4 MDM2 TP53
24 acute canaliculitis 10.4 CDKN2A MTOR
25 oro-mandibular-limb hypogenesis syndrome 10.4 CDKN2A ERBB2 TP53
26 ovarian cystadenocarcinoma 10.4 EGFR ERBB2 VEGFA
27 anomalous left coronary artery from the pulmonary artery 10.4 EGFR ERBB2 MTOR
28 urethral verrucous carcinoma 10.4 CDKN2A PTEN TP53
29 fragile x-associated tremor/ataxia syndrome 10.4 CDKN2A PDGFRA TP53
30 clear cell adenofibroma 10.4 CDKN2A TP53
31 tricuspid valve prolapse 10.4 CDKN2A EGFR PDGFRA
32 chronic monocytic leukemia 10.4 CDKN2A EGFR TP53
33 apocrine sweat gland neoplasm 10.4 CDK4 CDKN2A MDM2
34 acquired hemangioma 10.4 CDKN2A ERBB2 TP53
35 brain stem angioblastoma 10.4 CDK4 MDM2 TP53
36 episodic ataxia 10.4 CDK4 CDKN2A MDM2
37 thymus squamous cell carcinoma 10.4 CDKN2A EGFR TP53
38 secondary hyperparathyroidism of renal origin 10.4 CDKN2A EGFR TP53
39 fallopian tube benign neoplasm 10.4 EGFR MGMT TP53
40 adult syndrome 10.4 PIK3CA PTEN TP53
41 wolffian adnexal neoplasm 10.4 EGFR TP53
42 ossifying fibromyxoid tumor 10.4 CDK4 CDKN2A TP53
43 cervical verrucous carcinoma 10.4 CDKN2A MDM2 TP53
44 small intestinal sarcoma 10.4 MDM2 PDGFRA PTEN
45 skeletal tuberculosis 10.4 CDKN2A ERBB2
46 his bundle tachycardia 10.4 EGFR ERBB2 TP53
47 lacrimal gland adenoid cystic carcinoma 10.4 CDKN2A TP53
48 kidney clear cell sarcoma 10.4 EGFR PDGFRA PIK3CA
49 tumor of exocrine pancreas 10.4 CDKN2A EGFR VEGFA
50 fallopian tube carcinosarcoma 10.4 ERBB2 TP53 VEGFA

Graphical network of the top 20 diseases related to Glioblastoma:



Diseases related to Glioblastoma

Symptoms & Phenotypes for Glioblastoma

UMLS symptoms related to Glioblastoma:


headache, seizures

GenomeRNAi Phenotypes related to Glioblastoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.04 PIK3CA EGFR MTOR
2 Decreased viability GR00107-A-1 11.04 PRKCA
3 Decreased viability GR00173-A 11.04 PDGFRA
4 Decreased viability GR00221-A-1 11.04 PRKCA AKT3 PRKCB CDKN2A EGFR MTOR
5 Decreased viability GR00221-A-2 11.04 PRKCA AKT3 PRKCB PIK3CA CDK2
6 Decreased viability GR00221-A-3 11.04 AKT3 CDKN2A ERBB2 PDGFRA CDK2
7 Decreased viability GR00221-A-4 11.04 PRKCA AKT3 PRKCB CDKN2A EGFR ERBB2
8 Decreased viability GR00301-A 11.04 AKT3 CDK2
9 Decreased viability GR00342-S-1 11.04 PRKCA MTOR
10 Decreased viability GR00342-S-2 11.04 PRKCA MTOR
11 Decreased viability GR00342-S-3 11.04 PRKCA
12 Decreased substrate adherent cell growth GR00193-A-1 10.25 CDK2 PRKCB
13 Decreased substrate adherent cell growth GR00193-A-2 10.25 AKT3 CDK2 CDK4 EGFR MTOR PRKCB
14 Decreased substrate adherent cell growth GR00193-A-3 10.25 AKT3 CDK2 CDK4
15 Decreased substrate adherent cell growth GR00193-A-4 10.25 CDK2 CDK4
16 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 10.16 PRKCB PRKCH PTEN VEGFA AKT3 CDK4
17 Decreased viability with paclitaxel GR00179-A-1 10.11 EGFR ERBB2 MTOR
18 Decreased viability with paclitaxel GR00179-A-2 10.11 MTOR
19 Decreased viability with paclitaxel GR00179-A-3 10.11 MTOR EGFR
20 Decreased cell migration GR00055-A-1 10.1 AKT3 CDK4 EGFR MTOR PIK3CA PRKCA
21 Increased cell death HMECs cells GR00103-A-0 9.92 EGFR MDM2 PIK3CA PRKCA CDK2 PRKCB
22 Decreased cell proliferation GR00353-A 9.78 AKT3 CDK2 ERBB2 MTOR
23 Increased cell migration GR00055-A-3 9.73 EGFR MTOR PIK3CA PRKCA PRKCB PRKCH
24 Increased cell viability after pRB stimulation GR00230-A-1 9.63 AKT3 CDK2 CDK4 EGFR ERBB2 PRKCA
25 Increased transferrin (TF) endocytosis GR00363-A 9.44 ADGRB1 CDK2 CDK4 CDKN2A EGFR ERBB2
26 Increased colony dispersion (increased number of colonies and decreased number of cells per colony) GR00212-A 9.13 PRKCA MTOR PDGFRA

MGI Mouse Phenotypes related to Glioblastoma:

44 (show all 25)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.57 TP53 VEGFA ADGRB1 AKT3 CDK2 CDK4
2 cardiovascular system MP:0005385 10.49 PTEN TP53 VEGFA AKT3 CDK2 CDK4
3 cellular MP:0005384 10.49 PTEN TP53 VEGFA PDGFRA PIK3CA PRKCA
4 immune system MP:0005387 10.49 ADGRB1 AKT3 CDK2 CDK4 CDKN2A EGFR
5 hematopoietic system MP:0005397 10.48 ADGRB1 AKT3 CDK2 CDK4 CDKN2A EGFR
6 endocrine/exocrine gland MP:0005379 10.47 AKT3 CDK2 CDK4 CDKN2A EGFR ERBB2
7 behavior/neurological MP:0005386 10.44 GPNMB MDM2 MTOR PDGFRA PIK3CA PRKCB
8 growth/size/body region MP:0005378 10.43 MTOR PDGFRA PIK3CA PRKCH PTEN TP53
9 embryo MP:0005380 10.41 CDK2 CDK4 CDKN2A EGFR ERBB2 MDM2
10 mortality/aging MP:0010768 10.41 AKT3 CDK2 CDK4 CDKN2A EGFR ERBB2
11 neoplasm MP:0002006 10.41 GPNMB MDM2 MGMT NDRG2 PDGFRA PIK3CA
12 integument MP:0010771 10.39 PRKCH PTEN TP53 VEGFA CDK2 CDK4
13 nervous system MP:0003631 10.36 PDGFRA PIK3CA PRKCA PRKCB PTEN TP53
14 muscle MP:0005369 10.31 CDK2 CDK4 CDKN2A EGFR ERBB2 MDM2
15 digestive/alimentary MP:0005381 10.26 EGFR ERBB2 MDM2 PDGFRA PTEN TP53
16 liver/biliary system MP:0005370 10.13 CDK4 CDKN2A EGFR MDM2 PTEN TP53
17 normal MP:0002873 10.1 AKT3 CDK4 EGFR ERBB2 MDM2 MTOR
18 no phenotypic analysis MP:0003012 10.09 CDKN2A EGFR MDM2 MGMT MTOR PDGFRA
19 limbs/digits/tail MP:0005371 10.08 EGFR ERBB2 MDM2 PDGFRA PTEN TP53
20 reproductive system MP:0005389 10.03 PDGFRA PIK3CA PTEN TP53 VEGFA AKT3
21 pigmentation MP:0001186 9.97 CDK4 CDKN2A EGFR GPNMB MDM2 PDGFRA
22 renal/urinary system MP:0005367 9.92 CDK4 EGFR MDM2 MTOR PDGFRA PTEN
23 respiratory system MP:0005388 9.81 CDKN2A EGFR ERBB2 MGMT MTOR PDGFRA
24 skeleton MP:0005390 9.7 CDKN2A EGFR ERBB2 MDM2 MTOR NDRG2
25 vision/eye MP:0005391 9.32 TP53 VEGFA CDK2 CDK4 CDKN2A EGFR

Drugs & Therapeutics for Glioblastoma

Drugs for Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 574)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
3
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
4 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
5 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
8
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
9
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
10
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
11
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 498142 38904
12
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
13
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1 106-60-5 137
14
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
15
Procarbazine Approved Phase 3,Phase 2,Phase 1 671-16-9 4915
16
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
17
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
18
Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
19
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
20
Lomustine Approved Phase 3,Phase 2,Phase 1 13010-47-4 3950
21
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
22
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
23
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
24
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
25
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
26
chloroquine Approved, Vet_approved Phase 3,Phase 2,Phase 1 54-05-7 2719
27
Morphine Approved, Investigational Phase 3 57-27-2 5288826
28
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
29
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
30
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
31
Copper Approved Phase 2, Phase 3,Phase 1,Early Phase 1 15158-11-9, 7440-50-8 27099
32
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
33
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
34
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
35
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
36
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
37
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
38
Flucytosine Approved Phase 2, Phase 3,Phase 1 2022-85-7 3366
39
Dopamine Approved Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
40
Disulfiram Approved Phase 2, Phase 3,Phase 1,Early Phase 1 97-77-8 3117
41
Losartan Approved Phase 3 114798-26-4 3961
42
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 5281106 54677470
43
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
44
Norepinephrine Approved Phase 3 51-41-2 439260
45
Cyproheptadine Approved Phase 3 129-03-3 2913
46
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538
47
Vitamin C Approved, Nutraceutical Phase 3,Phase 2,Phase 1 50-81-7 5785 54670067
48
Camptothecin Experimental Phase 2, Phase 3,Phase 1 7689-03-4
49
Veliparib Investigational Phase 2, Phase 3,Phase 1 912444-00-9 11960529
50
Cediranib Investigational Phase 3,Phase 1,Phase 2 288383-20-0 9933475

Interventional clinical trials:

(show top 50) (show all 1203)
id Name Status NCT ID Phase
1 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4
2 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4
3 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
4 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Unknown status NCT01149109 Phase 3
5 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3
6 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
7 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3
8 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3
9 Enzastaurin Versus Lomustine in Glioblastoma Completed NCT00295815 Phase 3
10 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3
11 Nimotuzumab in Adults With Glioblastoma Multiforma Completed NCT00753246 Phase 3
12 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3
13 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3
14 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3
15 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3
16 Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme Completed NCT00068952 Phase 3
17 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3
18 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
19 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3
20 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3
21 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3
22 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3
23 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3
24 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3
25 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3
26 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3
27 Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors Completed NCT00088400 Phase 3
28 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3
29 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Completed NCT00379470 Phase 3
30 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3
31 A Study of Avastin® (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3
32 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3
33 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3
34 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3
35 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
36 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3
37 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3
38 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
39 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
40 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3
41 Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme Recruiting NCT02685605 Phase 3
42 Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma Recruiting NCT01507506 Phase 3
43 Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma Recruiting NCT02546102 Phase 3
44 Disulfiram in Recurrent Glioblastoma Recruiting NCT02678975 Phase 2, Phase 3
45 Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III Recruiting NCT02761070 Phase 3
46 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Recruiting NCT02617589 Phase 3
47 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3
48 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3
49 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Recruiting NCT02892708 Phase 3
50 A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) Active, not recruiting NCT02511405 Phase 3

Search NIH Clinical Center for Glioblastoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Glioblastoma

Genetic tests related to Glioblastoma:

id Genetic test Affiliating Genes
1 Glioblastoma 29

Anatomical Context for Glioblastoma

MalaCards organs/tissues related to Glioblastoma:

39
Brain, Endothelial, T Cells, Spinal Cord, Lung, Monocytes, Bone

Publications for Glioblastoma

Articles related to Glioblastoma:

(show top 50) (show all 3881)
id Title Authors Year
1
The Anti-Warburg Effect Elicited by the cAMP-PGC1I+ Pathway Drives Differentiation of Glioblastoma Cells into Astrocytes. ( 28076790 )
2017
2
Roles of zinc-fingers and homeoboxes 1 during the proliferation, migration, and invasion of glioblastoma cells. ( 28351300 )
2017
3
Microtubule actin cross-linking factor 1, a novel target in glioblastoma. ( 27959385 )
2017
4
New Directions in Anti-Angiogenic Therapy for Glioblastoma. ( 28083806 )
2017
5
E2F transcription factors associated with up-regulated genes in glioblastoma. ( 27983535 )
2017
6
Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRvIII Human Glioblastoma Cells. ( 28081256 )
2017
7
A continuous-infusion dynamic MRI model at 3.0 Tesla for the serial quantitative evaluation of microvascular proliferation in an animal model of glioblastoma multiforme. ( 28078795 )
2017
8
Advances in the targeting of HIF-1I+ and future therapeutic strategies for glioblastoma multiforme (Review). ( 27959421 )
2017
9
Humanized Chondroitinase ABC Sensitizes Glioblastoma Cells to Temozolomide. ( 28087981 )
2017
10
Potential mechanisms of microRNA-129-5p in inhibiting cell processes including viability, proliferation, migration and invasiveness of glioblastoma cells U87 through targeting FNDC3B. ( 28068630 )
2017
11
RYK promotes the stemness of glioblastoma cells via the WNT/ I^-catenin pathway. ( 28086236 )
2017
12
pH, Lactate, and Hypoxia: Reciprocity in Regulating High-Affinity Monocarboxylate Transporter Expression in Glioblastoma. ( 28092823 )
2017
13
GSH depletion and consequent AKT inhibition contribute to the Nrf2 knockdown-induced decrease in proliferation in glioblastoma U251 cells. ( 28260004 )
2017
14
Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells. ( 28035389 )
2017
15
Learning MRI-based classification models for MGMT methylation status prediction in glioblastoma. ( 28254081 )
2017
16
IQGAP1 in Podosomes/Invadosomes Is Involved in the Progression of Glioblastoma Multiforme Depending on the Tumor Status. ( 28098764 )
2017
17
Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma. ( 28070598 )
2017
18
The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment. ( 28089821 )
2017
19
Distant spread of a supratentorial glioblastoma to the spinal cord. ( 28089418 )
2017
20
Multicentric spinal cord glioblastoma. ( 28089804 )
2017
21
Interaction between transcription factors PAX6/PAX6-5a and specific members of miR-183-96-182 cluster, may contribute to glioma progression in glioblastoma cell lines. ( 28184912 )
2017
22
Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. ( 28011470 )
2017
23
Tumor Suppressor Candidate 1 Suppresses Cell Growth and Predicts Better Survival in Glioblastoma. ( 26897357 )
2017
24
Proliferative and Invasive Effects of Progesterone-Induced Blocking Factor in Human Glioblastoma Cells. ( 28168193 )
2017
25
15a89-methoxypuupehenol induces antitumor effects in vitro and in vivo against human glioblastoma and breast cancer models. ( 28069875 )
2017
26
Docetaxel-Loaded Nanoparticles Assembled from I^-Cyclodextrin/Calixarene Giant Surfactants: Physicochemical Properties and Cytotoxic Effect in Prostate Cancer and Glioblastoma Cells. ( 28533751 )
2017
27
Heat Shock Factor 1 Depletion Sensitizes A172 Glioblastoma Cells to Temozolomide via Suppression of Cancer Stem Cell-Like Properties. ( 28241425 )
2017
28
Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy. ( 28076333 )
2017
29
Suppression of p53-inducible gene 3 is significant for glioblastoma progression and predicts poor patient prognosis. ( 28351326 )
2017
30
FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of I^-catenin nuclear accumulation. ( 28260024 )
2017
31
A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo. ( 28181832 )
2017
32
Long non-coding RNA AC023115.3 suppresses chemoresistance of glioblastoma by reducing autophagy. ( 28499919 )
2017
33
Knockdown of Collagen Triple Helix Repeat Containing 1 (CTHRC1) Inhibits Epithelial-Mesenchymal Transition and Cellular Migration in Glioblastoma Cells. ( 28277194 )
2017
34
Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study. ( 28074320 )
2017
35
Mammalian target of rapamycin inhibitors, temsirolimus and torin 1, attenuate stemness-associated properties and expression of mesenchymal markers promoted by phorbol-myristate-acetate and oncostatin-M in glioblastoma cells. ( 28351321 )
2017
36
Knockdown of Ras-Related Protein 25 (Rab25) Inhibits the In Vitro Cytotoxicity and In Vivo Antitumor Activity of Human Glioblastoma Multiforme Cells. ( 28281975 )
2017
37
Cytologic features of pleomorphic xanthoastrocytoma, WHO grade II. A comparative study with glioblastoma. ( 28084690 )
2017
38
Motility of glioblastoma cells is driven by netrin-1 induced gain of stemness. ( 28069038 )
2017
39
Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma. ( 28079702 )
2017
40
MicroRNA-153 regulates glutamine metabolism in glioblastoma through targeting glutaminase. ( 28218035 )
2017
41
HMGCR positively regulated the growth and migration of glioblastoma cells. ( 26432005 )
2016
42
ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma. ( 26719046 )
2016
43
A Dexamethasone-regulated Gene Signature Is Prognostic for Poor Survival in Glioblastoma Patients. ( 27653222 )
2016
44
MicroRNA-520b affects the proliferation of human glioblastoma cells by directly targeting cyclin D1. ( 26700671 )
2016
45
High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma. ( 25983032 )
2016
46
The hedgehog antagonist HHIP as a favorable prognosticator in glioblastoma. ( 26482617 )
2016
47
De novo glioblastoma in the territory of a recent middle cerebral artery infarction and a residual meningioma: pathogenesis revisited. ( 27091344 )
2016
48
UBE2S, a novel substrate of Akt1, associates with Ku70 and regulates DNA repair and glioblastoma multiforme resistance to chemotherapy. ( 27593939 )
2016
49
LncRNA and mRNA expression profiles of glioblastoma multiforme (GBM) reveal the potential roles of lncRNAs in GBM pathogenesis. ( 27604987 )
2016
50
Hypervascular glioblastoma multiforme or arteriovenous malformation associated Glioma? A diagnostic and therapeutic challenge: A case report. ( 27999714 )
2016

Variations for Glioblastoma

ClinVar genetic disease variations for Glioblastoma:

6 (show top 50) (show all 62)
id Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.697C> T (p.Arg233Ter) single nucleotide variant Pathogenic rs121909219 GRCh37 Chromosome 10, 89717672: 89717672
2 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
5 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
6 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
7 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
8 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
9 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
10 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
11 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
12 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
13 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
14 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
15 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
16 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
17 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
18 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
19 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
20 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
21 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
22 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
23 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic/Likely pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
24 EGFR NM_005228.4(EGFR): c.2155G> T (p.Gly719Cys) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs28929495 GRCh37 Chromosome 7, 55241707: 55241707
25 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
26 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
27 BRAF NM_004333.4(BRAF): c.1787G> T (p.Gly596Val) single nucleotide variant Pathogenic/Likely pathogenic rs397507483 GRCh37 Chromosome 7, 140453148: 140453148
28 EGFR NM_005228.4(EGFR): c.2156G> C (p.Gly719Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913428 GRCh37 Chromosome 7, 55241708: 55241708
29 PIK3CA NM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
30 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
31 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
32 TP53 NM_000546.5(TP53): c.580C> T (p.Leu194Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587780071 GRCh37 Chromosome 17, 7578269: 7578269
33 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
34 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
35 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
36 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
37 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
38 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
39 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
40 MTOR NM_004958.3(MTOR): c.6644C> T (p.Ser2215Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 GRCh38 Chromosome 1, 11124516: 11124516
41 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh37 Chromosome 3, 178952074: 178952074
42 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
43 MTOR NM_004958.3(MTOR): c.4448G> T (p.Cys1483Phe) single nucleotide variant Pathogenic/Likely pathogenic rs786205165 GRCh37 Chromosome 1, 11217230: 11217230
44 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
45 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic/Likely pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947
46 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
47 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 GRCh37 Chromosome 8, 38272308: 38272308
48 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
49 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
50 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529

Copy number variations for Glioblastoma from CNVD:

7 (show all 37)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13758 1 1 28000000 Copy number Glioblastoma
2 30312 1 241718157 242073207 Amplification AKT3 Glioblastoma
3 33636 1 46800000 50700000 Copy number Glioblastoma
4 40021 10 123227833 123347962 Amplification FGFR2 Glioblastoma
5 42796 10 40200000 135534747 Loss Glioblastoma
6 51519 11 127400000 130300000 Loss Glioblastoma
7 70074 12 58100000 63100000 Copy number CDK4 Glioblastoma
8 71138 12 67700000 71500000 Copy number MDM2 Glioblastoma
9 74585 13 109204184 109236915 Amplification IRS2 Glioblastoma
10 87860 14 78400000 100400000 Loss Glioblastoma
11 106844 17 1 3600000 Loss Glioblastoma
12 109487 17 26446120 26728821 Deletion NF1 Glioblastoma
13 122049 18 52000000 76117153 Loss Glioblastoma
14 132099 19 57600000 63811651 Gain Glioblastoma
15 133731 19 6900000 13900000 Copy number CDKN2D Glioblastoma
16 137039 2 136600000 209100000 Gain Glioblastoma
17 187590 4 52700000 59500000 Amplification CHIC2 Glioblastoma
18 187591 4 52700000 59500000 Amplification IGFBP7 Glioblastoma
19 187592 4 52700000 59500000 Amplification KDR Glioblastoma
20 187593 4 52700000 59500000 Amplification KIT Glioblastoma
21 187594 4 52700000 59500000 Amplification KIT Glioblastoma
22 187596 4 52700000 59500000 Amplification LNX1 Glioblastoma
23 187597 4 52700000 59500000 Amplification PDGFRA Glioblastoma
24 187598 4 52700000 59500000 Amplification PDGFRA Glioblastoma
25 187599 4 52700000 59500000 Amplification RASL11B Glioblastoma
26 187600 4 52700000 59500000 Amplification REST Glioblastoma
27 187601 4 52700000 59500000 Amplification SEC3L1 Glioblastoma
28 187602 4 52700000 59500000 Amplification USP46 Glioblastoma
29 187603 4 52700000 59500000 Amplification VEGFR2 Glioblastoma
30 187604 4 52700000 59500000 Copy number Glioblastoma
31 207847 6 161688579 163068824 Deletion PARK2 Glioblastoma
32 226025 7 54000000 58000000 Copy number EGFR Glioblastoma
33 226576 7 59600001 66100000 Gain Glioblastoma
34 250055 9 19900000 33200000 Copy number CDKN2A Glioblastoma
35 253823 9 4600000 14200000 Deletion PTPRD Glioblastoma
36 253952 9 49000000 141213431 Loss Glioblastoma
37 255680 9 8304245 10602723 Deletion PTPRD Glioblastoma

Expression for Glioblastoma

Search GEO for disease gene expression data for Glioblastoma.

Pathways for Glioblastoma